Low-Dose DMC Significantly Enhances the Effect of TMZ on Glioma Cells by Targeting Multiple Signaling Pathways Both In Vivo and In Vitro

摘要: Temozolomide (TMZ) is widely used for treating glioblastoma (GBM), which can effectively inhibit the GBM growth some months; however, it still cannot prevent invariable recurrence of GBM. Improving chemotherapeutic sensitization becomes an urgent agenda. In this study, we found low-dose demethoxycurcumin (DMC) could enhance sensitivity TMZ on glioma cells, and high-dose DMC has more significant effects cells compared with treatment alone both in vitro vivo. And co-administration resulted a increase apoptosis marked inhibition cell pathogenesis Mechanistically, synergistically intracellular level reactive oxygen species (ROS) production, activate caspase-3-dependent apoptotic pathway, inactivate JAK/STAT3 signaling pathway GBMs, account proliferation inhibition. Together, these data implicate that combined represents effective therapy regimen against GBMs by targeting multiple pathways.